ERBB2 and breast carcinoma: To test whether NAX014 can reduce breast cancer cell migration and invasion, the HER-2 overexpressing human SK-BR-3 and murine TUBO cell lines were treated with low doses of NAX014 (0.5, 2, or 10 μM) for 48 h, and subjected to trans-well migration assay.